This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Novartis (NVS) Tops on Q2 Earnings, Ups Operating Income View
by Zacks Equity Research
Novartis' (NVS) second-quarter earnings and sales beat estimates. Based on strong momentum, the company raises its operating income outlook for 2024.
Syros (SYRS) Stock Rises More Than 35% in 3 Months: Here's Why
by Zacks Equity Research
Syros (SYRS) is progressing well with the development of its pipeline candidate, tamibarotene, which is being studied for two different cancer indications.
Roche (RHHBY) Reports Positive Phase I Data on Obesity Drug
by Zacks Equity Research
Roche's (RHHBY) obesity candidate, CT-996, demonstrates clinically meaningful weight loss in the ongoing phase I study.
Roche Holding's (RHHBY) Accu-Chek SmartGuide Receives CE Mark
by Zacks Equity Research
Roche Holding (RHHBY) announces the receipt of CE Mark for its Accu-Chek SmartGuide CGM solution which is intended toward providing better diabetes management.
Here's Why Sarepta (SRPT) Stock Price Surged 57% YTD
by Zacks Equity Research
Sarepta (SRPT) surges on the commercial potential of its Elevidys, the first FDA-approved gene therapy for Duchenne muscular dystrophy.
The Zacks Analyst Blog Highlights Eli Lilly, Sanofi Merck, AstraZeneca's and Roche
by Zacks Equity Research
Eli Lilly, Sanofi Merck, AstraZeneca's and Roche are included in this Analyst Blog.
Pharma Stock Roundup: FDA Nod to LLY's Kisunla, SNY's Dupixent Gets EU Nod for COPD
by Kinjel Shah
Eli Lilly (LLY) wins FDA approval for its Alzheimer's disease drug, Kisunla. (donanemab). Sanofi (SNY) and Regeneron's Dupixent gets approval for COPD in Europe.
Roche (RHHBY) Receives FDA Nod for Vabysmo Prefilled Syringe
by Zacks Equity Research
The FDA approves Roche's (RHHBY) Vabysmo prefilled syringe for treating three retinal conditions that can cause blindness.
Roche's (RHHBY) Combo Therapy Misses Lung Cancer Study Goals
by Zacks Equity Research
Roche (RHHBY) announces that its mid to late-stage lung cancer study evaluating the tiragolumab combination therapy compared with Keytruda fails to meet primary endpoints.
Roche (RHHBY) Gets Positive CHMP Recommendation for Its Drugs
by Zacks Equity Research
Roche (RHHBY) gets CHMP recommendation for a label expansion of ophthalmology drug Vabysmo (faricimab) and PiaSky (crovalimab) for the treatment of paroxysmal nocturnal haemoglobinuria.
Roche's (RHHBY) Ocrevus Subcutaneous Gets European Commission Nod
by Zacks Equity Research
Roche (RHHBY) obtains approval for the subcutaneous formulation of relapsing multiple sclerosis drug Ocrevus in Europe. In addition, a review of the company's MAA for gene therapy, Elevidys, is also underway.
FDA Expands Sarepta's (SRPT) DMD Gene Therapy Label
by Zacks Equity Research
Following the label expansion, Sarepta's (SRPT) Elevidys is approved to treat all DMD patients aged four years and older, regardless of ambulation status.
Roche (RHHBY), Ascidian Team Up for RNA Exon Editing Therapeutics
by Zacks Equity Research
Roche (RHHBY) gets exclusive, target-specific rights to Ascidian's RNA exon editing technology for undisclosed neurological targets for an initial payment of $42 million.
Regeneron (REGN) Outperforms Industry YTD: What Lies Ahead?
by Zacks Equity Research
Regeneron (REGN) maintains momentum on the back of Dupixent profits and efforts to develop oncology portfolio despite near-term challenges.
Roche (RHHBY) Reports Upbeat Data on Columvi From STARGLO Study
by Zacks Equity Research
Roche's (RHHBY) Columvi significantly extends survival in patients with relapsed or refractory diffuse large B-cell lymphoma in the phase III STARGLO study.
Roche (RHHBY) NSCLC Drug Alecensa Gets EC Nod for Label Expansion
by Zacks Equity Research
Roche's (RHHBY) Alecensa gets the European Commission's approval as the first and only targeted adjuvant treatment for people with ALK-positive early-stage lung cancer.
The Zacks Analyst Blog Highlights Roche, Wells Fargo, General Aerospace and Key Tronic
by Zacks Equity Research
Roche, Wells Fargo, General Aerospace and Key Tronic are part of the Zacks top Analyst Blog.
Top Analyst Reports for Roche, Wells Fargo & GE Aerospace
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Roche Holding AG (RHHBY), Wells Fargo & Company (WFC) and GE Aerospace (GE), as well as a micro-cap stock Key Tronic Corporation (KTCC).
Affimed (AFMD) Soars on Upbeat Follow-Up Data From NSCLC Study
by Zacks Equity Research
Affimed (AFMD) rallies 69% on positive follow-up efficacy data from its early to mid-stage study of the AFM24/Tecentriq combo therapy to treat heavily-pretreated EGFR wild-type NSCLC patients.
Novartis (NVS) Reports Positive Long-Term Data on CSU Drug
by Zacks Equity Research
Novartis (NVS) reports phase III data that confirm sustained efficacy and long-term safety of oral remibrutinib in chronic spontaneous urticaria.
Pharma Stock Roundup: JNJ, MRK M&A Deals, SNY, RHHBY Drugs' Priority Review & More
by Kinjel Shah
J&J (JNJ) and Merck (MRK) announce the acquisitions of private biotechs. The FDA grants Priority Review tags to Sanofi's (SNY) and Roche's (RHHBY) regulatory applications.
Roche's (RHHBY) Inavolisib NDA Gets FDA Priority Review Tag
by Zacks Equity Research
The FDA grants priority review to Roche's (RHHBY) NDA for the inavolisib combination regimen for advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation.
Puma Biotechnology (PBYI) Falls 38% in 3 Months: Here's Why
by Zacks Equity Research
Sales of Puma Biotechnology's (PBYI) sole marketed drug, Nerlynx, have been declining in recent quarters. Stiff competition in the target market is also a woe.
Regeneron (REGN) Announces Positive Data on Oncology Candidate
by Zacks Equity Research
Regeneron's (REGN) REGN7075, in combination with its oncology drug Libtayo, generates anti-tumor responses in patients with microsatellite-stable colorectal cancer.
Pharma Stock Roundup: AZN's 2030 Sales Target, PFE's New Cost Cut Plan & More
by Kinjel Shah
AstraZeneca (AZN) announces an ambitious target of achieving $80 billion in revenues by 2030. Pfizer (PFE) announces a multi-year, multi-phase cost reduction program.